NK Cell Therapy With BHV-1100
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 25 patients (estimated)
- Sponsors
- Biohaven Pharmaceuticals, Inc.
- Tags
- Natural Killer (NK) Cells, CD38
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1110
- NCT Identifier
- NCT04634435
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.